Evaluation of in-vitro activity of Ceftazidime-Avibactam and Aztreonam combination therapy against MBL and Non-MBL producing strains of Pseudomonas aeruginosa

Thomas J; Nabamita Bhaumik; Subbalakshmi Easwaran

doi:10.24321/doi.org/10.24321/0019.5138.202595

Thomas J Assistant Professor, Department of Microbiology, School of Allied Health Sciences, Vinayaka Missions Research Foundation- DU, Vims Hospital Campus, Salem, India
Nabamita Bhaumik Postgraduate Student, Department of Clinical Microbiology, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
Subbalakshmi Easwaran Postgraduate Student, Department of Clinical Microbiology, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

DOI: https://doi.org/10.24321/doi.org/10.24321/0019.5138.202595

Keywords: Antimicrobial resistance, synergy testing, Carbapenem resistance, CZA-ATM testing, MBL non-MBL producers

Author Biographies

Nabamita Bhaumik, Postgraduate Student, Department of Clinical Microbiology, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

Postgraduate student, Department of Microbiology

Subbalakshmi Easwaran, Postgraduate Student, Department of Clinical Microbiology, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

Professor, Department of Microbiology

References

1. Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022 Dec;11(1):811–4.
2. Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Clin Infect Dis. 1983 Mar 1;5(2):279–313.